Number of items: 1.
Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer (HR-NMIBC) With FGFR3/2 Alterations (alt) in THOR-2: Cohort 2 Interim Analysis Results. (2023)
James W.F. Catto,
Ben Tran,
Viraj A. Master,
Morgan Roupret,
Geraldine Pignot,
Andrea Tubaro,
Nobuaki Shimizu,
Nikhil Vasdev,
Juergen Gschwend,
Yohann Loriot,
Hiyoyuki Nishiyama,
Joan Redorta,
Siamak Daneshmand,
Yuji Miura,
Vahid Naini,
Lauren Crow,
Spyros Triantos,
Mahadi Baig
and
Gary D. Steinberg
This list was generated on Fri May 29 01:27:11 2026 BST.